CTI BioPharma Corp.
CTI BioPharma Corp., a prominent player in the biopharmaceutical industry, is headquartered in the United States, with significant operations across various regions. Founded in 1991, the company has made substantial strides in developing innovative therapies for blood-related cancers, particularly focusing on conditions such as leukaemia and lymphoma. CTI BioPharma is renowned for its flagship product, pacritinib, a unique treatment designed for patients with myelofibrosis, a rare bone marrow disorder. This product stands out due to its targeted mechanism of action, offering hope to those with limited treatment options. Over the years, CTI BioPharma has achieved notable milestones, including successful clinical trials and strategic partnerships, solidifying its position in the competitive biopharmaceutical landscape. With a commitment to advancing patient care, CTI BioPharma continues to drive innovation in oncology therapeutics.
DitchCarbon Score
How does CTI BioPharma Corp.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
CTI BioPharma Corp.'s score of 46 is lower than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
CTI BioPharma Corp., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Swedish Orphan Biovitrum AB (publ), which may influence its climate commitments and reporting practices. While CTI BioPharma Corp. has not established its own reduction targets or initiatives, it is important to note that any climate commitments or performance metrics may be inherited from its parent company, Swedish Orphan Biovitrum AB (publ). This relationship suggests that CTI BioPharma may align its sustainability efforts with the broader goals set by its parent organisation. As of now, CTI BioPharma Corp. has not publicly committed to specific science-based targets or other industry-standard climate initiatives. The lack of emissions data and defined reduction strategies highlights an opportunity for the company to enhance its environmental accountability and contribute to global climate efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 156,000 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 129,000 | 000,000 | 00,000 | 0,000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 3 | 922,000 | 0,000,000 | 0,000,000 | - | - | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
CTI BioPharma Corp. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
